Dyne Therapeutics (DYN) Competitors $26.16 +0.06 (+0.23%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DYN vs. QGEN, ITCI, ROIV, ASND, RVMD, LNTH, LEGN, NUVL, BPMC, and ELANShould you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Qiagen (QGEN), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), Nuvalent (NUVL), Blueprint Medicines (BPMC), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Dyne Therapeutics vs. Qiagen Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Revolution Medicines Lantheus Legend Biotech Nuvalent Blueprint Medicines Elanco Animal Health Qiagen (NYSE:QGEN) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations. Which has better valuation & earnings, QGEN or DYN? Qiagen has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.97B5.26$341.30M$0.39116.26Dyne TherapeuticsN/AN/A-$235.94M-$3.56-7.35 Do institutionals and insiders hold more shares of QGEN or DYN? 70.0% of Qiagen shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 20.8% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate QGEN or DYN? Qiagen presently has a consensus price target of $51.15, suggesting a potential upside of 12.82%. Dyne Therapeutics has a consensus price target of $50.42, suggesting a potential upside of 92.72%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60Dyne Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.08 Does the media favor QGEN or DYN? In the previous week, Dyne Therapeutics had 3 more articles in the media than Qiagen. MarketBeat recorded 14 mentions for Dyne Therapeutics and 11 mentions for Qiagen. Qiagen's average media sentiment score of 0.98 beat Dyne Therapeutics' score of 0.72 indicating that Qiagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is QGEN or DYN more profitable? Qiagen has a net margin of 4.73% compared to Dyne Therapeutics' net margin of 0.00%. Qiagen's return on equity of 13.43% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Qiagen4.73% 13.43% 8.10% Dyne Therapeutics N/A -57.46%-51.62% Does the MarketBeat Community favor QGEN or DYN? Qiagen received 216 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Dyne Therapeutics an outperform vote while only 60.88% of users gave Qiagen an outperform vote. CompanyUnderperformOutperformQiagenOutperform Votes24960.88% Underperform Votes16039.12% Dyne TherapeuticsOutperform Votes3373.33% Underperform Votes1226.67% Which has more risk and volatility, QGEN or DYN? Qiagen has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. SummaryQiagen and Dyne Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Ad Brownstone ResearchDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYN vs. The Competition Export to ExcelMetricDyne TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.66B$6.83B$5.14B$9.30BDividend YieldN/A3.06%4.76%4.06%P/E Ratio-7.3510.45134.4517.49Price / SalesN/A283.891,255.89139.10Price / CashN/A56.6540.5537.96Price / Book17.565.424.894.91Net Income-$235.94M$150.67M$118.26M$225.23M7 Day Performance-7.66%-5.39%14.52%-1.43%1 Month Performance-7.85%0.43%17.48%5.40%1 Year Performance105.98%16.12%35.86%22.84% Dyne Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYNDyne Therapeutics3.1855 of 5 stars$26.16+0.2%$50.42+92.7%+106.0%$2.66BN/A-7.35100QGENQiagen4.2311 of 5 stars$45.42+0.0%$51.15+12.6%+3.6%$10.36B$1.97B117.035,967ITCIIntra-Cellular Therapies4.1678 of 5 stars$84.52+1.8%$97.23+15.0%+32.9%$8.96B$612.78M-95.91560ROIVRoivant Sciences2.667 of 5 stars$12.14+2.5%$17.93+47.7%+8.9%$8.84B$129.13M2.10860Positive NewsASNDAscendis Pharma A/S3.2197 of 5 stars$135.74+4.5%$191.77+41.3%+16.0%$8.23B$327.43M-16.52640Short Interest ↑RVMDRevolution Medicines4.6632 of 5 stars$44.89-0.3%$63.67+41.8%+69.6%$7.55B$11.58M-12.54443Positive NewsLNTHLantheus4.4014 of 5 stars$94.27+1.3%$130.00+37.9%+21.9%$6.55B$1.50B15.42834Positive NewsLEGNLegend Biotech1.6722 of 5 stars$33.83-3.7%$81.54+141.0%-43.4%$6.18B$520.18M-36.971,800NUVLNuvalent2.3475 of 5 stars$86.65-0.2%$112.60+29.9%+9.7%$6.16BN/A-25.0340Positive NewsBPMCBlueprint Medicines2.9172 of 5 stars$95.39+2.4%$122.11+28.0%+9.7%$6.06B$249.38M-44.17640Insider TradeShort Interest ↑ELANElanco Animal Health4.2802 of 5 stars$12.09-0.1%$16.75+38.5%-10.5%$5.98B$4.45B30.259,300 Related Companies and Tools Related Companies Qiagen Competitors Intra-Cellular Therapies Competitors Roivant Sciences Competitors Ascendis Pharma A/S Competitors Revolution Medicines Competitors Lantheus Competitors Legend Biotech Competitors Nuvalent Competitors Blueprint Medicines Competitors Elanco Animal Health Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DYN) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DYN Stock Alerts